We’re helping solve our customers’ big challenges by innovating and delivering solutions that are better for their business—and for the environment.

Project At-a-Glance:

The opportunity: Working together with the University Health Network’s Toronto Western Hospital and sustainable energy leader Noventa® Energy Partners, Trane® helps implement the world’s largest wastewater thermal energy project.

The solution: A custom designed and engineered heat pump system including:

Trane® chiller heat pumps containing ultra-low global warming potential (GWP) refrigerants – Agility HDWA, CenTraVac CVHH, RTWDTrane system controls, including enterprise building management system Tracer® Ensemble with integrated work order managementTrane Digital Services including Intelligent Services, Analytics and active alarm monitoring

Sustainability outcomes:

Low-carbon energy powers 90% of the HVAC needs of a 1.5 million square-foot hospital campusCarbon emissions reduction of 8,400 metric tons/yearWater use reduction of 45 million litres/year1.8 billion kilowatt-hours of low-carbon energy over the life of the project19 megawatts of low-carbon thermal energy capacityOver 2,400 tons of low-carbon cooling capacityOver 33,000 MBTU of low-carbon heating capacity

University Health Network’s (UHN) Toronto Western Hospital in Toronto, Canada, has been a leader in sustainable practices for over twenty years. Guided by their motto “UHN: Practicing Patient and Planet Centred Care,” UHN has won multiple awards for innovative programming that incorporates care for the planet into their patient care model. 

As a further step on the path toward sustainability, Toronto Western hoped to reduce energy use and carbon emissions. To help the hospital realize that goal, UHN tapped renewable energy leader Noventa Energy Partners, famous for their groundbreaking Wastewater Energy TransferTM, or WET® technology, to take advantage of thermal energy from the city’s municipal sewage system to heat and cool their campus.

WET technology replaces conventional heating and cooling systems with a heat transfer process based on recovering thermal energy from wastewater. Whereas most hospitals rely on greenhouse gas-emitting natural gas combustion to heat their facilities, the thermal energy contained in wastewater is low-carbon, highly reliable and renewable energy. 

Though most people don’t ever think about it, wastewater contains abundant thermal energy. It represents a potentially massive unused resource that only requires the will — and the expertise — to make good use of it. 

Assembling the decarbonization A-Team

As remarkable as a WET system is, it doesn’t function on its own. It requires a heat pump as a connection point between the wastewater system and the hospital’s HVAC. Noventa looked to Trane® for that critical link. For the system to make financial sense, the heat pump must be extremely efficient.

Another key reason Noventa chooses Trane for these large-scale projects is the depth of knowledge and capability in Trane engineering equipment and automation solutions and the quality and efficiency of the products. The expertise at Trane and the knowledge to successfully execute large and complex building automation and controls projects while integrating them into existing hospital systems allowed for efficient construction. Implementing the WET solution required working with the hospital without disrupting operations and ongoing coordination with local utilities and the City of Toronto. 

The WET technology system connects directly to Toronto’s sewer system, which remains at a stable temperature throughout the year. The system removes solids from wastewater at the sewer level, then a self-cleaning heat exchanger eliminates the need to handle wastewater inside the buildings. To integrate the recovered thermal energy into the existing HVAC system, a highly efficient, high-temperature capable heat pump is required.  

In summer, the system employs Trane chiller heat pumps containing ultra-low global warming potential (GWP) refrigerants that reject heat into the sewers. The result: the building is cooled without the need for cooling towers, which would otherwise consume energy and potable water. In winter, heat is extracted from the sewer system, and Trane chiller heat pumps supply the hospital with reliable hot water.

In addition to the heat pumps, the system leverages Trane system controls, including a Trane Tracer® Ensemble, enterprise-wide building management system, valves and meters to control and maximize system operation. Analytics and fault detection diagnostics built into the Trane automation system manage the equipment’s performance under various conditions to ensure a reliable energy supply.

Results

At 19 megawatts, Toronto Western’s WET system is currently the world’s largest raw wastewater energy project. The system is capable of supplying 1.8 billion kilowatt-hours of energy, over 2,400 tons of cooling, and over 33,000 MBH of heating.

The WET system will supply 90 percent of the energy needed to heat and cool the hospital’s 1.5 million square foot campus. In total, it eliminates 8,400 metric tons of carbon emissions per year — the equivalent of the carbon output of 1,800 gasoline-powered cars.

“We’re honored to partner with Noventa for Toronto Western Hospital to pursue their mission of practicing patient and planet-centered care,” said Lukas Glaspell, Trane Account Executive. “As a purpose-driven organization ourselves, we know that human and planetary health are closely linked. Alongside Noventa, we’re proud to support clients like Toronto Western in improving both.”

CENTENNIAL, Colo., June 12, 2024 /3BL/ – When it comes to advancing mobility, Arrow Electronics is helping to set a new course. With an advanced processor made by NVIDIA, Arrow has designed a first of its kind, AI-powered steering system that uses facial recognition technology to control its latest SAM (Semi-Autonomous Mobility) Car.

Quadriplegic racecar driver Sam Schmidt recently drove at competitive speeds using the new system that he steers through head motions. Arrow engineers developed the new steering system using the latest NVIDIA Jetson AGX Orin module, the only platform capable of delivering the high accuracy and low latency needed to control a car at speeds up to 213 mph.

A low-profile stereo camera pair located on the dash captures Schmidt’s movements in real time and feeds the data to the NVIDIA module. Using machine learning, the system processes the information and adjusts the steering angle automatically – within a few thousandths of a second. 

The new AI steering replaces the car’s original four-camera steering that used an older, infrared motion-capture based technology.

“With the AI, it’s more controllable,” said Schmidt. “There’s no lag. It’s instantaneous for high speed.”

The steering enhancements could have everyday applications far beyond the racetrack. The technology could be used to control vehicles and large equipment in settings as different as farming, warehouses, public transit and construction so the operator – physically disabled or not – could perform multiple tasks. 

“The SAM Car has evolved into a technology platform that really personifies enabling the benefit of technology for as many people as possible,” said Murdoch Fitzgerald, Arrow vice president of global engineering and design services.

About Arrow Electronics
Arrow Electronics guides innovation forward for thousands of leading technology manufacturers and service providers. With 2023 sales of $33 billion, Arrow develops technology solutions that help improve business and daily life. Learn more at arrow.com.

###

Luciana Preger credits being exposed to her father’s work at a young age with helping inform her own career in medicine. Luciana is a physician with more than 20 years of experience in pharma and she came to Gilead to help transform treatments for people living with cancer.

“As a child, I loved the opportunity to go on rounds with my father at the hospital in Rio de Janeiro and witness the bedside connections he made with patients,” says Luciana, Vice President, Global Medical Affairs, Oncology. “To this day, I carry with me the emotion that I saw on those rounds at a young age. I don’t want to ever forget that.”

Improving outcomes and access to medicine for people living with disease drives her work. In fact, it was Gilead’s legacy of expanding global access to life-changing medicines that first attracted Luciana to the company, as she longed to be in an environment where she could play a bigger role in bridging the gap between scientific innovation and patient care.

“To truly transform the way cancer is treated, oncology advances must be built on a foundation of equitable care,” she says. “There is no scientific innovation without clear access to it, and access to care is at the forefront of all our work at Gilead.”

Luciana’s career has spanned three continents, from her home country of Brazil to France and the U.S. To have a greater impact in oncology, she felt it was a unique opportunity to be in the Silicon Valley to collaborate directly with renown leaders working on the cutting edge of cancer research and treatment.

Before coming to Gilead, she worked with teams that developed more than 10 oncology therapies — most of them have demonstrated survival benefits in multiple cancers.

These days Luciana is most excited to talk about Gilead’s growing oncology portfolio. More than 30,000 patients have been reached with one of the company’s medicines, and it continues to explore where the medicine can have the greatest impact for people across many difficult-to-treat tumor types.

In Luciana’s role she oversees the strategic direction of Global Medical Affairs initiatives and priorities in oncology, ensuring they help advance scientific understanding of the company’s therapies. Her team drives the dissemination of clinical data by helping review and publish the findings, engaging with key opinion leaders, supporting external research and creating educational programs to inform clinical practices.

All in all, Luciana is pleased to be at a company that is committed to helping people who need its medicines most. “What we do is meaningful. We play a role in helping to prolong life and addressing the unmet needs of people living with cancer worldwide,” she says. “Ultimately, we want to achieve cure and take back possibility in the face of cancer.”

Originally published by Gilead Sciences

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.